Assessing commercial feasibility: a practical and ethical prerequisite for human clinical testing.
This article proposes that an assessment of commercial feasibility should be integrated as a prerequisite for human clinical testing to improve the quality and relevance of materials being investigated, as an ethical aspect for human subject protection, and as a means of improving accountability where clinical development is funded on promises of successful translational research. A commercial feasibility analysis is not currently required to justify human clinical testing, but is assumed to have been conducted by industry participants, and use of public funds for clinical trials should be defensible in the same manner. Plant-made vaccines (PMVs) are offered in this discussion as a model for evaluating the relevance of commercial feasibility before human clinical testing. PMVs have been proposed as a potential solution for global health, based on a vision of immunizing the world against many infectious diseases. Such a vision depends on translating current knowledge in plant science and immunology into a potent vaccine that can be readily manufactured and distributed to those in need. But new biologics such as PMVs may fail to be manufactured due to financial or logistical reasons--particularly for orphan diseases without sufficient revenue incentive for industry investment--regardless of the effectiveness which might be demonstrated in human clinical testing. Moreover, all potential instruments of global health depend on translational agents well beyond the lab in order to reach those in need. A model compromising five criteria for commercial feasibility is suggested for inclusion by regulators and ethics review boards as part of the review process prior to approval of human clinical testing. Use of this model may help to facilitate safe and appropriate translational research and bring more immediate benefits to those in need.
Kirk
Dwayne D
DD
School of Life Sciences, Arizona State University, P.O. Box 874501, Tempe, AZ 85287-4501, USA. dwayne.kirk@asu.edu
Robert
Jason Scott
JS
D001709:Biotechnology / Q000191:economics; D002986:Clinical Trials as Topic / Q000191:economics / Q000941:ethics / Q000592:standards; D003906:Developing Countries; D017277:Drug Approval / Q000191:economics; D004345:Drug Industry / Q000191:economics; D026724:Ethical Review; D006805:Human Experimentation / Q000941:ethics; D006801:Humans; D030821:Plants, Genetically Modified / Q000276:immunology; D035583:Rare Diseases / Q000517:prevention & control; D012109:Research Support as Topic; D013673:Technology Assessment, Biomedical; D014612:Vaccines / Q000096:biosynthesis* / Q000191:economics* / Q000600:supply & distribution
D014612:Vaccines